ResMed Inc. vs Zillow Group Inc Class A — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: ResMed Inc. is far larger — about 4.8× Zillow Group Inc Class A's market cap, and ResMed Inc. pays a 1.16% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Zillow Group Inc Class A for 86 Days on average.
| RMD | ZG | |
|---|---|---|
Market Cap | $31.89B | $6.59B |
Volume | 618,314 | 1,361,381 |
Sector | Health | Media |
52-Week High | $277.88 | $74.58 |
52-Week Low | $182.82 | $27.70 |
Typical Hold Time | 51 Days | 86 Days |
Enterprise Value | $31.24B | $6.47B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Zillow Group (ZG) trades at $29.53, up 5.58% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported a return to profitability in 2025 with net income of $23 million, and revenue is projected to grow to $2.8 billion in 2026. Recent news highlights the company's focus on AI integration and a challenging housing market environment.
The outlook is cautiously optimistic, with a consensus price target of $48.87 suggesting significant upside. Key opportunities include revenue growth and market share gains, while risks involve housing market volatility and intense competition. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →